Glaukos Corporation (NYSE:GKOS) Files An 8-K Submission of Matters to a Vote of Security Holders

Glaukos Corporation (NYSE:GKOS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Story continues below

The annual meeting of stockholders (the “Annual Meeting”) of Glaukos Corporation (the “Company”) was held on May31, 2018.At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 18, 2018.

The final voting results for each matter submitted to a vote of stockholders at the Annual Meeting are as follows:

Proposal 1.The election of three Class III directors to hold office until the 2021 annual meeting of stockholders or until their respective successors are duly elected and qualified:

For

Withheld

Broker Non‑Votes

Thomas W. Burns

22,584,973 4,460,727 4,228,474

Gilbert H. Kliman, M.D.

22,564,362 4,481,338 4,228,474

Marc A. Stapley

22,565,699 4,480,001 4,228,474

Proposal 2.The non-binding advisory vote regarding approval of the compensation of the Company’s named executive officers:

For

Against

Abstain

Broker Non-Votes

18,877,839

8,139,386

28,475

4,228,474

Proposal 3.The non-binding advisory vote regarding the frequency of future advisory votes on the compensation of the Company’s named executive officers:

One Year

Two Years

Three Years

Abstain

Broker Non-Votes

25,745,505

22,281

955,958

321,956

4,228,474

In light of the foregoing vote results, on May 31, 2018, the Board of Directors of the Company approved every one year as the frequency of future advisory votes on executive compensation until the next say-on-frequency vote required by applicable rules of the Securities and Exchange Commission.

Proposal 4. The ratification of the appointment of Ernst& Young LLP as the Company's independent registered public accounting firm for the year ending December31, 2018:

1,

For

Against

Abstain

31,138,501

84,566

51,107


About Glaukos Corporation (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

An ad to help with our costs